Radient Pharmaceuticals Corporation fka RXPC

[primarywatcher]

BioMed Reports pushing news again...just in time for the lunch crowd

Report: Shares of Radient Pharmaceuticals Breaking Out Ahead of Growth and Debt-to-Equity Approval
http://www.marketwire.com/press-release/Report-Shares-Radient-Pharmaceuticals-Breaking-Out-Ahead-Growth-Debt-Equity-Approval-NYSE-Amex-RPC-1372413.htm

LOS ANGELES, CA, Dec 21, 2010 (MARKETWIRE via COMTEX) -- Shares of Radient Pharmaceuticals (RPC) are breaking out and look set to go higher ahead of an ambitious debt-to-equity plan recently approved by the company.

After Monday's session, the stock closed up 56.55% but analysts believe the stock should continue to see significant appreciation in advance of several forward looking news events and developments.

Officials at Radient, which is listed on the NYSE Amex are seeking approval for a significant debt-to-equity exchange which was approved by company shareholders on December 3rd at its Annual Meeting.

While the board and shareholders voted in favor of the execution of a financial stabilization plan that should take company from tens of millions of dollars in debt to close to $30 million in equity, the stock actually sunk lower in the days following the news. Not only did the markets need time to digest the details of
the ambitious exchange terms, but as it appears, some funds started naked-shorting the stock.

Motivated by several factors, the shorts also anticipated that approval of the debt-to-equity exchange might be delayed; or perhaps not approved by regulators at the NYSE Amex. The company has not only submitted all of the approved proposals and related issuances to the NYSE Amex for their approval but word of
that approval could come any day.

The company is also expecting positive news from the Mayo Clinic in regards to a clinical study for the validation of RPC's US FDA-approved Onko-Sure in vitro diagnostic (IVD) cancer test for diagnosing lung cancer. RPC's low-cost test, which has already been validated for the detection of several types of cancerous
tumors, enables physicians and their patients to effectively monitor and/or detect solid tumor cancers much earlier than other tests by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products.

The impact of a validation for the test as an early screening device for lung cancer could be a significantly positive development not only to the company's financial outlook but also to the vast populations who are at-risk for developing lung cancer. Results from that validation are also rumored to be "only a couple of weeks away."

The American Cancer Society estimates that Lung cancer is responsible for the most cancer deaths in both men and women throughout the world. Lung cancer was not common prior to the 1930s but increased dramatically over the following decades as tobacco smoking increased. In many developing countries, the incidence of lung cancer has started to fall following public education about the dangers of cigarette smoking and effective smoking cessation programs, but it remains the most common form of cancer in men worldwide and the fifth most common form of
cancer in women.

Several government sponsored medical agencies in these developing countries have begun to reach out to RPC and their sales partners in order to place orders for their low-cost cancer tests. We have, in recent weeks, begun to see an increase in these types of orders from foreign entities as disclosed in public documents
and company announcements.

In addition, the company has started exploring options and looked into expanding their production capabilities in order to meet the growing demand. Order fulfillment figures, even without growth in manufacturing capacities, could provide RPC tens of millions of dollars in new revenues next year. BioMedReports has reached out to the management of Radient Pharmaceuticals for an update on these developments and a full report will follow as soon as we can prepare it for publication. We fully expect that increased foreign sales of the Onko-Sure cancer test will continue and more announcements about foreign orders may be coming in the weeks ahead.

From a technical analysis standpoint, we see that the stock has traded between $0.20 and $2.59 this year and we feel that shares should appreciate significantly from these levels. In fact, given the vast short interest in the stock our estimates for price appreciation may turn out to be conservative. Figures which
reflect short interest in the stock- not including the previously mentioned naked shorts- account for almost 5% of the entire float.

A perfect storm of short squeezing, similar to the one seen last April when the stock rose from around $0.30 to over $2.00 could be ready to play out here.

Investors interested in reading the full special report, complete with research links and technical analysis charts may do so at:

http://biomedreports.com/2010122161661/shares-of-radient-pharmaceuticals-break-out-and-headed-higher.html

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can also access that information at:
http://biomedreports.com/fda-calendar/fda-calendar.html